Biosimilars – Forecast – Endocrinology
In 2023, sales of insulins at the ex-manufacturer price level exceeded $19 billion in the major pharmaceutical markets under study (United States, EU5, and Japan); G7 sales for Prolia exceeded $3 billion. Throughout our 2023-2033 forecast period, the originator insulins manufactured by Eli Lilly, Novo Nordisk, and Sanofi as well as Amgen / Daiichi Sankyo’s Prolia / Pralia will face increasing competition from biosimilars / follow-on insulins, eroding both patient share and drug prices. We present our forecast for key reference brand insulins and antiresorptive analogues and their biosimilars / follow-on insulins by therapeutic area, molecule, and country / region.
Table of contents
- Biosimilars - Forecast - Endocrinology
Related Market Assessment Reports
Report
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
